368 related articles for article (PubMed ID: 20067471)
21. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
22. Influence of the hOCT2 inhibitor cimetidine on the cellular accumulation and cytotoxicity of oxaliplatin.
Buss I; Kalayda GV; Marques-Gallego P; Reedijk J; Jaehde U
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):51-4. PubMed ID: 19203538
[No Abstract] [Full Text] [Related]
23. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
24. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.
Sauzay C; White-Koning M; Hennebelle I; Deluche T; Delmas C; Imbs DC; Chatelut E; Thomas F
Pharmacol Res; 2016 Aug; 110():89-95. PubMed ID: 27178732
[TBL] [Abstract][Full Text] [Related]
26. Glycosylated Platinum(IV) Complexes as Substrates for Glucose Transporters (GLUTs) and Organic Cation Transporters (OCTs) Exhibited Cancer Targeting and Human Serum Albumin Binding Properties for Drug Delivery.
Ma J; Wang Q; Huang Z; Yang X; Nie Q; Hao W; Wang PG; Wang X
J Med Chem; 2017 Jul; 60(13):5736-5748. PubMed ID: 28603992
[TBL] [Abstract][Full Text] [Related]
27. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
28. Celecoxib antagonizes the cytotoxicity of oxaliplatin in human esophageal cancer cells by impairing the drug influx.
Kong Y; Gu C; Zhong D; Zhao X; Lin Q; Wang K; Xun T; Yu L; Liu S
Eur J Pharm Sci; 2016 Jan; 81():137-48. PubMed ID: 26474693
[TBL] [Abstract][Full Text] [Related]
29. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
30. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
31. cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects.
Lovejoy KS; Todd RC; Zhang S; McCormick MS; D'Aquino JA; Reardon JT; Sancar A; Giacomini KM; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Jul; 105(26):8902-7. PubMed ID: 18579768
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10.
Hector S; Nava ME; Clark K; Murphy M; Pendyala L
Cancer Lett; 2007 Jan; 245(1-2):195-204. PubMed ID: 16516375
[TBL] [Abstract][Full Text] [Related]
33. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
Wang S; Zhang H; Scharadin TM; Zimmermann M; Hu B; Pan AW; Vinall R; Lin TY; Cimino G; Chain P; Vuyisich M; Gleasner C; Mcmurry K; Malfatti M; Turteltaub K; de Vere White R; Pan CX; Henderson PT
PLoS One; 2016; 11(1):e0146256. PubMed ID: 26799320
[TBL] [Abstract][Full Text] [Related]
34. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.
Pestell KE; Hobbs SM; Titley JC; Kelland LR; Walton MI
Mol Pharmacol; 2000 Mar; 57(3):503-11. PubMed ID: 10692490
[TBL] [Abstract][Full Text] [Related]
35. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
Mellish KJ; Barnard CF; Murrer BA; Kelland LR
Int J Cancer; 1995 Sep; 62(6):717-23. PubMed ID: 7558420
[TBL] [Abstract][Full Text] [Related]
36. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.
Luo FR; Wyrick SD; Chaney SG
Cancer Chemother Pharmacol; 1999; 44(1):29-38. PubMed ID: 10367746
[TBL] [Abstract][Full Text] [Related]
37. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
38. Changes in the in vitro activity of platinum drugs when administered in two aliquots.
Al-Eisawi Z; Beale P; Chan C; Yu JQ; Proschogo N; Molloy M; Huq F
BMC Cancer; 2016 Aug; 16(1):688. PubMed ID: 27566066
[TBL] [Abstract][Full Text] [Related]
39. Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family.
Chen Y; Zhang S; Sorani M; Giacomini KM
J Pharmacol Exp Ther; 2007 Aug; 322(2):695-700. PubMed ID: 17495125
[TBL] [Abstract][Full Text] [Related]
40. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
